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Summary Trabectedin is a novel anticancer drug active
against soft tissue sarcomas. Trabectedin is a substrate for
P-glycoprotein (P-gp), which is encoded by mdr1a/1b in
rodents. Plasma and tissue distribution, and excretion of
[14C]-trabectedin were evaluated in wild-type and mdr1a/1b
(−/−) mice. In parallel, we investigated the toxicity profile
of trabectedin by serial measurements of blood liver
enzymes and general pathology. [14C]-trabectedin was
extensively distributed into tissues, and rapidly converted
into a range of unknown metabolic products. The excretion
of radioactivity was similar in both genotypes. The plasma
clearance of unchanged trabectedin was not reduced when
P-gp was absent, but organs under wild type circumstances
protected by P-gp showed increased trabectedin concentra-
tions in mdr1a/1b(−/−) mice. Although hepatic trabectedin
concentrations were not increased when P-gp was absent,
mdr1a/1b(−/−) mice experienced more severe liver toxicity.
P-gp plays a role in the in vivo disposition and toxicology
of trabectedin.
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Introduction
Trabectedin (ET-743, Yondelis™) belongs to the ecteinas-
cidins, which are tetrahydro-isoquinoline compounds iso-
lated from the marine tunicate Ecteinascidia turbinata
[1–3]. Intravenous trabectedin (ET-743, Yondelis™,
Fig. 1) is approved as monotherapy in Europe for use in
patients with advanced soft tissue sarcomas (STS) after
failure of anthracyclines and ifosfamide, or in patients who
are unsuited to receive those agents [4]. Trabectedin has
received orphan drug status for treating STS and for
treating recurrent ovarian cancer in the United States and
Europe [5].
Structurally, trabectedin is composed of three tetrahy-
droisoquinoline subunits and a central carbinolamine moiety,
which enables it to bind covalently to DNA, see Fig. 1 [6].
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Trabectedin displays sequence-specific binding to the
minor groove of duplex DNA, bending the double helix
towards the major groove and affecting the transcription of
genes, including the MDR1 gene (ABCB1) that codes for
P-gp [7–11].
Trabectedin is a very potent compound. The approved
dose is 1.5 mg/m2 every 3 weeks, resulting in total doses of
approximately 3 mg by i.v. infusion over 24 h. These doses,
in combination with a very large volume of distribution
(Vss, 1,000 to 4,000 L [12]), result in plasma concentrations
in the picogram to low nanogram per mL range. Trabectedin
also displayed a large volume of distribution (Vss, 15–20 L/kg
[13]) in laboratory animals. The excretory fate of trabectedin
is largely unknown. In rats, less than 0.5% of the dose
administered was recovered in bile as trabectedin, suggesting
an important role for metabolism in the elimination of
trabectedin [13]. Urinary excretion of trabectedin in man is
reported to be less than 1% of the dose administered, and
biliary excretion of unchanged trabectedin is also very low
[14–16], indicating that metabolism is the major route of
elimination. However, the pathways involved in the metab-
olism of trabectedin are largely unknown. Isolation of
metabolites from biological matrices and further structural
elucidation is very difficult because of their very low
concentrations [15]. Metabolic and degradation products
were identified after incubation with human serum, liver
microsomes, and UDP-glucuronyl transferase [14], and in
vitro studies with liver microsomes suggest that trabectedin
is mainly metabolized by CYP3A4 and to a minor extent by
CYPs 2C9, 2C19, 2D6 and 2E1 [13, 17].
Although clinically, dose-limiting toxicities are primarily
related to the effects of trabectedin on bone marrow,
hepatotoxicity, as manifested by transient elevation of
serum liver enzymes, is frequently observed with all
administration schedules [12]. The biochemical basis of
the liver toxicity is unknown. Intriguingly, the magnitude of
the elevation of liver enzymes diminishes after repeated
cycles. A possible explanation is that there are changes in
the expression of enzymes or transporters involved in
elimination of trabectedin and/or its metabolites.
Recent in vitro investigations in our institute have shown
that trabectedin is a P-gp substrate; however, P-gp only
confers resistance to trabectedin when expressed at high
levels [18], and there are reports suggesting resistance to
trabectedin by non-P-gp related pathways [19, 20], includ-
ing a deficiency in transcription-coupled nucleotide-
excision repair [21].
Besides the association of P-gp expression with reduced
cytotoxicity in tumor cells and with therapeutic failure,
P-gp can also play an important role in the plasma
pharmacokinetics and tissue distribution of its substrates
[22–27]. P-gp is expressed at high levels at specific organ-
barriers like the blood–brain barrier, the blood–testis
barrier, and the blood–placenta barrier and limits the entry
of substrate drugs into these sanctuary sites. Moreover,
P-gp is expressed in organs like the gut, liver and kidneys
where it is involved in the excretion of drugs from the body
[27]. Therefore, we designed a study using P-gp-deficient
(mdr1a/1b(−/−)) mice [23] to explore the role of P-gp in the
disposition and toxicity of trabectedin in vivo.
Materials and methods
Drugs and chemicals
[14C]trabectedin, provided by PharmaMar (Madrid, Spain),
originated from Biodynamics Radiochemicals (Billingham,
UK) and was purified by HPLC to >97.5% radiochemical
purity [16]. Non-labelled trabectedin was provided as
lyophilized product for injection by PharmaMar. [D6]
trabectedin was provided by PharmaMar (Madrid, Spain).
Bovine serum albumin fraction V (BSA) was obtained
from Roche Diagnostics GmBH (Mannheim, Germany).
Water was purified by the Milli-Q Plus® system (Millipore,
Milford, USA). All other chemicals were of analytical grade.
Animals
FVB wild-type (WT) and P-gp knock-out type (mdr1ab(−/−))
mice, 9–14 weeks of age, were housed and handled in
accordance with Dutch national law. The animals had access
to food (Hope Farms B.V., Woerden, The Netherlands) and
acidified water ad libitum. All experiments were approved
by the local ethics committee for animal experiments.
Maximum tolerable dose
To establish the single administration maximum tolerable
dose (MTD) of trabectedin, groups (6 mice each) of male
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Fig. 1 Chemical structure of trabectedin and the position of the 14C-
label in [14C]trabectedin
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and female wild-type and mdr1a/1b(−/−) mice were dosed
at 50, 100, 150, 200, 250 and 300 μg/kg and monitored
for 14 days. Mice were euthanized upon loss of 20% of
the initial body weight, and counted as a toxic death.
The MTD was defined as the highest dose level where
none of 6 mice died as a consequence of the drug, loss
of body weight of individual mice did not exceed 20%,
or the average loss of body weight in the group did not
exceed 15%.
Hepatotoxicity
To investigate the role of P-gp in the hepatotoxicity of
trabectedin, male and female wild-type and mdr1a/1b(−/−)
mice (9 mice per group) were dosed at their respective
MTD. Female mdr1a/1b(−/−) mice were also dosed at
150 μg/kg, which is below their MTD, to allow comparison
with male mdr1a/1b(−/−) mice. The liver function param-
eters alanine aminotransferase (ALAT/SGPT), aspartate
aminotransferase (ASAT/SGOT), total bilirubin and alkaline
phosphatase (AP) were monitored daily for up to 7 days by
serial blood sampling. Jaundice was defined as macroscopic
observation of yellow-colored skin of the mice. Blood
samples were collected in heparinized glass capillaries and
transferred into polypropylene vials followed by centrifuga-
tion (10 min, 6,000×g). A 20–25 μl aliquot of plasma was
diluted fourfold with saline and assayed the same day by a
Hitachi 917 Analyzer (Roche Diagnostics, Indianapolis, IN,
USA) using standard protocols.
Pathology
Autopsies were performed at day 4 or day 14 after
trabectedin administration at the respective MTD (N=2
per group). Expert pathology reports were prepared by a
trained animal Pathologist of the Netherlands Cancer
Institute.
Tissue disposition
To investigate the tissue distribution of [14C]trabectedin,
we dosed male wild-type and mdr1a/1b(−/−) mice with
150 μg/kg [14C]trabectedin. At 7 min, 20 min, and 1, 3,
8, 24, 48 and 96 h after administration, 4 animals of
each genotype were exsanguinated by cardiac puncture
under methoxyflurane (Medical Developments, Springvale,
Australia) anesthesia and euthanized by cervical disloca-
tion. The tissues dissected for analysis of radioactivity
included: plasma (from blood from the heart), brains,
muscle (from the back), abdominal fat, colon, cecum, small
intestine, stomach (all emptied), liver, gallbladder, kidneys,
lungs, spleen, heart, thymus, abdominal lymph nodes, testes,
epidydimus, adrenal glands, bone, skin and pancreas.
Tissues that were only analyzed for total radioactivity
content were weighed and dissolved in 1 mL Solvable
tissue solubilizer (Packard, Groningen, The Netherlands),
followed by quantitation of radioactivity. Other tissues were
analyzed for both total radioactivity and parent drug, and
were weighed and homogenized in 2 mL of a 4% bovine
serum albumin solution in water. Brains and liver were
homogenised in 3 and 5 mL, respectively, and plasma was
diluted with at least 1 volume of 4% BSA. A 200-μL
aliquot of each homogenate was analyzed for radioactivity
by liquid scintillation counting after addition of 4 mL of
Ultima Gold scintillation fluid (Packard, Groningen, The
Netherlands). Counting was performed using a Tricarb
2300 TR Liquid Scintillation Analyzer (Packard, Meriden,
CT, USA) with automating quench correction.
Tissues homogenized with 4% BSA were assayed for
trabectedin concentration using an adapted validated LC-
MS/MS method [28]. After addition of [D6]-trabectedin as
internal standard, 500 μL aliquots of homogenate were
extracted twice with 5 mL of diethyl ether. Pooled organic
layers were evaporated to dryness under a gentle stream of
nitrogen, and stored at −20°C until analysis. Reconstitution
was performed by vortexing and sonication (5 min) with
200 μL of methanol-5 mM ammonium acetate, 0.4%
formic acid (75:25, v/v) (the mobile phase). Quantitation
was performed using [14C]trabectedin calibration samples
(spiked to the respective blank tissue homogenate), that had
been processed identically to the samples. Recovery was
between 50 and 80%, and the lower limit of quantitation
(LLQ) was 50–100 pg/mL homogenate, depending on the
specific tissue involved.
Excretion
The excretion of [14C]trabectedin was studied in wild-type
and mdr1a/1b(−/−) male mice (N=4 per genotype) placed
in Ruco Type M/1 metabolic cages (Valkenswaard, The
Netherlands). At 8, 24, 48, 72 and 96 h after [14C]
trabectedin administration, urine and feces were collected,.
Urine and feces samples were weighed, and feces were
homogenized in 10 parts 4% BSA. Radioactivity determi-
nation of the dosing solution and the biological samples
was performed by liquid scintillation counting after
addition of 4 mL (to 200 μL urine) or 12 mL (to 200 μL
feces homogenate or 100 μL of dosing solution 1:20)
Ultima Gold scintillation fluid.
Metabolism
The metabolism of trabectedin was investigated by gall-
bladder cannulation [29] of a single WT mouse (male,
13 weeks). Bile was collected for 1.5 h following intrave-
nous administration of 200 μg [14C]-trabectedin/kg body
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weight. A 20-μL aliquot of bile was diluted 20-fold in
methanol:phosphate buffered saline (1:10, v/v) followed by
extraction with 4 mL of diethylether. After shaking (5 min),
the aqueous layer was frozen using ethanol and dry-ice. The
organic layer was separated and evaporated to dryness under
a gentle stream of nitrogen followed by reconstitution in
400 μL of methanol:phosphate buffered saline (1:10, v/v).
The aqueous phase was diluted (1:1, v/v) with methanol:
phosphate buffered saline (1:10, v/v). Each solution was
injected onto a Symmetry C18 column (150×4.6 mm,
3.5 μm, Waters, Milford, USA). A binary gradient was
applied at 1 mL/min using two Spectroflow SF400 pumps
(Kratos, Ambacht, The Netherlands). Mobile phase A
consisted of 10 mM ammonium acetate + 0.04% formic acid
(pH=4.0), and mobile phase B consisted of methanol:10 mM
ammonium acetate + 0.04% formic acid (30:70, v/v). An
18-min linear gradient from 43% to 100% B was followed
by 100%B until 23 min. Eluate fractions were collected every
18 s. After addition of 3 mL scintillation fluid, radioactivity
was determined off-line by liquid scintillation counting.
Data analysis
AUC values were calculated in Excel (Microsoft Corporation,
Redmond,WA) based on the linear trapezoidal rule. Statistical
analysis of AUC values consisted of calculation of themdr1a/
1b(−/−) to wild-type AUC ratio with the associated standard
error (SE). After log-transformation, these ratios were
subjected to a two-sided Students t-test, under the null-
hypothesis of log(AUC-ratio)=0.
Excretion of radioactivity in urine, feces, and the total
excretion of [14C]-trabectedin in mdr1a/1b(−/−) and wild-type
male mice was compared with a two-sided Students t-test.
A value of p<0.05 was considered statistically significant.
Results
Maximum tolerable dose
The MTD of trabectedin was 250 μg/kg in both male and
female wild-type mice. However, we observed a sex-based
difference in the mdr1a/1b(−/−) mice. Male mice were
more sensitive, as the MTD was 150 μg/kg whereas the
MTD in females was 250 μg/kg, see Table 1. Mice
receiving trabectedin at dose levels exceeding the MTD
suffered from general malaise (manifested by inactivity and
pilo-erection) which most likely caused insufficient food
and fluid intake. Animals were euthanized when their body
weight loss exceeded 20%. Other macroscopic signs of
toxicity were mild alopecia behind the ears of female
mdr1a/1b(−/−) mice, and occasional jaundice, particularly
in male mdr1a/1b(−/−) mice.
Hepatotoxicity
Elevation of liver enzymes is common after administration
of trabectedin to cancer patients. The biochemical basis of
this hepatotoxicity is unknown. In this study, we have
explored the role of P-gp in the hepatotoxicity of trabectedin
in mice by serial determination of liver enzymes in plasma.
None of the mice in these series experienced more than 20%
loss of body weight during the observation period, and the
toxicity profile was similar to that in the mice used for the
determination of the MTD. Only male and female mdr1a/1b
(−/−) mice displayed mild jaundice. Levels of plasma ALAT,
ASAT, bilirubin, and AP are presented in Fig. 2. Given the
large inter-animal variability in plasma liver enzyme eleva-
tions, the number of animals used did not allow rigorous
statistical analysis between all groups. In general, ALAT,
ASAT and bilirubin levels increased at 24 h after dosing,
reached a maximum within approximately 3 days, and
returned to baseline levels after approximately 1 week.
Plasma levels of AP started to increase after 48 h, and
reached a maximum at 4 days after dosing. On an
opportunistic basis we re-dosed a cohort of male wild-type
and female mdr1a/1b(−/−) mice with 250 μg/kg trabectedin,
6 weeks after the first dose. This resulted in a slightly
increased hepatotoxicity pattern in the female mdr1a/1b(−/−)
mice, whereas hepatotoxicity was decreased in the male
wild-type mice.
Pathology
Bone marrow was depleted in all the mice euthanized
4 days after dosing, but had recovered by day 14. Small
Table 1 Determination of the maximum tolerable dose (MTD) of
trabectedin in male and female wild-type and mdr1a/1b(−/−) mice
Dose Wild-type mdr1a/1b(−/−)
Male Female Male Female
μg/kg N † N † N † N †
50 3 0 7 0 – – – –
100 3 0 7 0 3 0 – –
150 3 0 7 0 6 0 3 0
200 3 1a 7 0 3 2 3 0
250 6 0 6 1b 3 3 6 0
300 3 1 3 1 3 3 3 1
350 3 3 3 2 – – – –
MTD 250 μg/kg 250 μg/kg 150 μg/kg 250 μg/kg
a This death was not considered drug-related as it showed an atypically
sharp decline in body-weight starting the day of administration
b This death was excluded as the mouse suffered from a tail-
inflammation at the site of injection
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focal degeneration of hepatic tissue was observed in all
male and female mdr1a/1b(−/−) mice at both the day 4 and
14 time points, which in approximately half the cases was
accompanied by signs of cholangitis and bile duct prolif-
eration. Because this was a different cohort of mice than the
mice used in the hepatotoxicity study, the presence of
cholangitis and bile duct proliferation could not be
correlated with biochemical parameters such as ALAT,
ASAT, AP or bilirubin. In female mdr1a/1b(−/−) mice only,
degeneration of the kidney tubules and hypotrophic
degeneration of the heart muscle were observed. In all of
the female mdr1a/1b(−/−) mice, the incisors showed
degeneration of the dentine. Degeneration of the intervertebral
discs was observed across all groups, apparently without a
specific pattern.
Tissue disposition
P-gp can have a major impact on the disposition of
substrate drugs such as trabectedin. We therefore investi-
gated the effect of P-gp on [14C]trabectedin disposition.
Results are shown in Fig. 3 and Table 1.
The total plasma radioactivity versus time profile after
administration of [14C]trabectedin was similar in wild-type
and mdr1a/1b(−/−) male mice. LC-MS/MS quantification
of trabectedin in plasma revealed that trabectedin is rapidly
metabolised. At 20 min and 3 h after administration, only
about 40 and 10% respectively of the radioactivity in
plasma represented unchanged trabectedin. The plasma
concentration versus time profile of unchanged trabectedin
in mdr1a/1b(−/−) and wild-type mice were similar during
the first hours after drug administration (Table 2).
The tissue-to-plasma ratios showed that radioactivity is
extensively distributed from plasma to tissues, in both wild-
type and mdr1a/1b(−/−) mice. Tissue-to-plasma ratios of
[14C]trabectedin were always larger than unity, except for
the brain in wild-type mice. In most tissues, radioactivity
was initially eliminated rapidly, followed by a slower
terminal elimination phase. Exceptions were the spleen,
thymus, lymph nodes, testis of both genotypes and the
brain of mdr1a/1b(−/−) mice, which displayed prolonged
retention of radioactivity.
The effect of the absence of P-gp on the tissue distri-
bution is most pronounced in the mdr1a/1b(−/−) brain (13-
fold increase) and testis (twofold increase) relative to the
wild-type controls. Differences were also observed in the
small intestines, kidneys, and heart, all organs known to
express P-gp [22–27].
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Fig. 2 Changes in plasma liver enzyme concentrations (mean±
standard deviation) after administration of trabectedin to male
(squares) and female (circles) wild-type (solid) and mdr1a/1b(−/−)
(open) mice. Bilirubin and AP were undetectable in wild-type males
and females. AP alkaline phosphatase; On an opportunistic basis, male
wild-type (X) and female mdr1a/1b(−/−) mice (open triangle) were re-
injected 6 weeks after the first dosing. N=9 per group
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LC-MS/MS quantitation of trabectedin in tissues
showed that only a fraction of radioactivity was
accounted for by unchanged compound. In brain at
7 min after dosing, trabectedin accounted for approxi-
mately 25% and 20% of radioactivity in mdr1a/1b(−/−)
and wild-type mice, respectively. Thereafter, trabectedin
concentrations in wild-type brain fell below the LLQ
while trabectedin concentrations were maintained at a
higher level in mdr1a/1b(−/−) brain. At 20 min after
administration, trabectedin accounts for approximately
20% and 10% of testis radioactivity in mdr1a/1b(−/−)
and wild-type mice, respectively. The trabectedin ratio in
mdr1a/1b(−/−) to wild-type testis at that time point was
approximately 4.5. Liver concentrations of trabectedin
represented only 1.5% or less of radioactivity at 8 h after
administration and were similar in mdr1a/1b(−/−) and
wild-type mice. These results indicate the importance of
P-gp in trabectedin disposition.
1000.0 1000
100
100.0
10.0
1.0
10
1
g)
Ti ( i )
q.
/g
00 30 60 90 120
me m n
-
eq
n
g-
.
 
(n
n
c.
co
n
a
 c
m
a
0.1
1000.0
100.0
10.0
1.0
0.1
1000.0
100.0
10.0
1.0
0.1
a
sm
Pl
a
P
1000. 0 100.0
10.0
100 0. 1.0
g)
q.
/g
0.1
10 0
-
eq
0 2 4.
n
g-
.
 
(n
n
c.
1.0
co
n
n
 c
a
in
B
r
0.1
B
1000. 0
)
/g
)
q.
/
100 0
g-
e
.
n
g
.
 
(
n
c
co
n
t. 
c
es
t
10 0
n
te
.
ll 
in
m
a
l
Sm
Time (h)Time (h)
Time (h) Time (h)
S
100.0
10.0
)
/g
)
eq
.
/
100.0
g-
e
10 0
(n
g
.
1.0
c.
 
(
1 0
n
c
.
co
n
0.1
is 
c
0 1 2 3
es
ti
0.1
TeT
0 12 24 36 48 60 72 84 96
 
0 12 24 36 48 60 72 84 96
 
0 12 24 36 48 60 72 84 96
0 12 24 36 48 60 72 84 96
Time (h)
0 12 24 36 48 60 72 84 96
Time (h)
0 12 24 36 48 60 72 84 96
a b
c d
e f
/g
)
q.
/
1000
-
eq
100
n
g
c.
(n
10
n
c
co
1
rt
 
c
0 1 2 3 4 5 6 7 8
ea
r
H
e
H
g)
.
/g
eq
g-
e
(n
g
n
c.
(
o
n
r 
co
v
er
L
iv
L
Fig. 3 Organ radioactivity [14C]trabectedin equivalents (circles) and
unchanged trabectedin (triangles) concentration versus time curves in
wild-type (closed) and mdr1a/1b(−/−) (open) male mouse plasma (a),
brain (b), testis (c), small intestines (d), heart (e), and liver (f). N=4
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Excretion and metabolism
We determined the effect of P-gp on the excretion of [14C]
trabectedin in wild-type and mdr1a/1b(−/−) mice (Fig. 4).
Feces was the predominant excretory pathway in both wild-
type (70.6±13.9%) and mdr1a/1b(−/−) mice (75.4±2.3%).
The contribution of urinary excretion (2.3±1.3% and 2.2±
0.9%, respectively) to total recovery (72.9±13.1% and 77.6±
2.5%, respectively) was minimal.
No significant differences were observed in urinary, fecal
or total excretion between the wild-type and mdr1a/1b(−/−)
mice (P≥0.50 for fecal, urinary, and total excretion at all
time points). Given the finding that only a small fraction of
radioactivity in plasma and tissues was unchanged drug, we
anticipated that unchanged trabectedin was only a minor
component of the excreted radioactivity. In that intra-
intestinal degradation of trabectedin may occur, we fitted
a single, male, wild-type mouse with a cannulated bile duct
to investigate the composition of the excreted radioactivity
in the bile (0–90 min sample). The resulting radiochro-
matogram is shown in Fig. 5 with trabectedin eluting at
about 11.4 min, and representing only about 2.5% of the
total radioactivity of the bile sample. The total bile sample
collected over 1.5 h contained approximately 1.6% of the
radioactive dose administered. Because the concentration of
the compounds in the sample was very low and the UV
chromatogram of the fractionation (not shown) indicated
the presence of large amounts of matrix-derived interfer-
ences, further structure analysis of fractions (e.g. by means
of mass spectrometry) was not feasible. Trabectedin
appeared to be extensively metabolised to a large number
of more polar as well as less polar metabolites, and was
itself only a minor contributor to biliary excretion, even
within the first 1.5 h after dosing.
Table 2 Area under the tissue concentration versus time curves for radioactive [14C]trabectedin equivalents in wild-type and mdr1a/1b(−/−) male
mice, the respective tissue-to-plasma ratios and the mdr1a/1b(−/−) to wild-type ratios
Organ Wild-type mdr1a/1b(−/−) mdr1a/1b(−/−)/
wild-type ratio
AUC (μg×h/g) SE Tissue/plasma-ratio AUC (μg×h/g) SE Tissue/plasma-ratio
Plasma 0.371 0.055 1.0 0.420 0.039 1.0 1.1
Brains 0.188 0.019 0.51 2.48 0.09 5.9 13.2*
Muscle 2.07 0.09 5.6 2.88 0.46 6.8 1.4
Fat 7.33 1.12 19.8 6.58 0.84 15.7 0.90
Colon 74.8 5.1 202 85.6 5.2 204 1.14
Caecum 133.9 18.7 361 120.3 12.2 286 0.90
Small intest. 8.46 0.18 22.8 12.1 0.4 28.7 1.4**
Stomach 49.0 3.5 132 55.9 1.9 133 1.1
Liver 12.2 0.7 32.8 12.2 0.4 29.1 1.0
Gallbladder 555.1 123.7 1,498 426.4 84.9 1,015 0.77
Kidneys 9.99 0.28 27.0 8.47 0.35 20.2 0.85***
Lungs 15.8 0.9 42.6 18.1 1.0 43.1 1.2
Spleen 36.2 1.1 97.6 30.1 3.3 71.6 0.83
Heart 4.61 0.19 12.4 6.46 0.19 15.4 1.4**
Thymus 71.3 6.9 192 73.3 9.2 175 1.0
Lymph nodes 99.06 22.92 267 127.9 8.0 304 1.3
Testes 0.802 0.045 2.2 1.68 0.07 4.0 2.1**
Epidymidus 0.815 0.105 2.2 0.653 0.032 1.6 0.80
Adrenals 5.16 0.41 13.9 5.62 0.72 13.4 1.1
Bone 1.70 0.12 4.6 1.70 0.08 4.0 1.0
Skin 2.37 0.22 6.4 3.11 0.32 7.4 1.3
Pancreas 84.1 4.1 227 82.7 3.6 197 0.98
*p<0.001
**p<0.01
***p<0.05
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Discussion
This study shows that the in vivo disposition of trabectedin
is affected by P-gp. As expected, P-gp decreases the
penetration of trabectedin into the brain and the testis as
they are protected by a specific blood–organ barrier
expressing P-gp. We also observed a decreased penetration
of the heart, confirming earlier reports on doxorubicin
disposition that suggest a role for P-gp in decreasing
cardiac exposure to xenobiotics [24]. However, the effect
of P-gp on trabectedin disposition in the heart is smaller
than in the brain or testis because this organ is not shielded
by a blood–organ barrier, although the heart endothelium
does express P-gp.
In contrast to reports on other P-gp substrate drugs
[30–32], we did not observe a decreased clearance of
unchanged trabectedin in mdr1a/1b(−/−) mice. The reason
that the clearance is not reduced in mdr1a/1b(−/−) mice
may be that metabolic clearance is the most important route
of elimination of trabectedin. As our data show, liver
concentrations of total radioactivity and unchanged trabec-
tedin are high and unaffected by P-gp status. Other P-gp
substrates that do show a decreased clearance in mdr1a/1b
(−/−) mice, are commonly excreted unchanged in sub-
stantial amounts by the liver or gut and a major part of this
excretion is mediated by P-gp [29, 33]. As only a minor
fraction of the radioactivity that was excreted into the bile
of a wild-type mice represented unchanged trabectedin, the
absence of P-gp in mdr1a/1b(−/−) mice was probably
unable to significantly decrease the trabectedin clearance.
In the disposition study, the male mdr1a/1b(−/−) and
wild-type mice received trabectedin at the same dose of
150 μg/kg and this resulted in similar plasma exposure.
This dose, however, was not equitoxic to both strains as it
was well below the MTD of wild-type mice but at the MTD
of the mdr1a/1b(−/−) mice. Therefore, the difference in the
MTD between male mdr1a/1b(−/−) and male wild-type
mice cannot satisfactorily be explained by a difference in
plasma exposure to trabectedin. Similarly, while there was
no difference in the trabectedin accumulation in the liver
between the two strains, we did observe a more severe
hepatotoxicity in the mdr1a/1b(−/−) mice. The absence of a
clear relationship between plasma and liver exposure to
trabectedin and toxic effects might suggest that metabolites
of trabectedin are involved in the toxicity, and that they
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may be P-gp substrates. The bile experiment showed that
the liver excreted a large number of radioactive trabectedin
metabolites, in agreement with the human metabolic profile
of trabectedin [15, 16]. Besides a range of more polar
compounds, we also observed several hydrophobic metab-
olites in bile, which is different from the reports in humans.
Due to the low quantities of these metabolites, further
structural characterization (e.g. by mass spectrometry) was
not feasible. Earlier in vitro studies have shown that human
metabolism of trabectedin is mediated by CYP450 enzymes
with a major role for 3A4 and minor contributions of 2C9,
2C19, 2D6, and 2E1 [13, 17]. The expression of CYP450
enzymes (including CYP3A2, the rodent counterpart of
human CYP3A4) in rats and mice is known to be sex-
dependent [34, 35]. Moreover, there are reports of changes
in CYP450 expression in mdr1a/1b(−/−) relative to wild-
type mice [36]. In addition, expression of other transporters
may also be modified in mdr1a/1b(−/−) as compared to
wild-type mice. A recent study suggested a role for the
multidrug resistance related proteins (Mrp2, Mrp3 and
Mrp4 in the hepatotoxicity of trabectedin [37].
Consequently, gender and strain differences in CYP450
enzymes expression resulting in variations in the metabolic
fate of trabectedin may partly explain the observed differ-
ences in toxicity at similar plasma exposures. In future
studies, it may be advisable to determine the expression
levels of CYP enzymes and other known drug transporters.
Our experiments confirm earlier reports that hepatotoxicity
of trabectedin in mice is non-cumulative and reversible [38].
This is in parallel with humans [39–41] but opposed to rats
where plasma ASAT, AP and bile acid levels remained
elevated for several months after dosing [12, 42, 43].
Therefore, the mouse appears to be a better species than
rats as a model of trabectedin-induced hepatotoxicity
trabectedin. However, metabolic profiles highly differ
between species, with major differences between mice, dogs
and rats, and greater similarity between human and primate
metabolism, and therefore the best model was reported to
be a monkey model [44, 45]. The decreased hepatotoxic
response of wild-type mice after a repeated injection of
trabectedin may be due to up-regulation of detoxifying
pathways. Interestingly, we did not observe a decreased
hepatotoxicity in mdr1a/1b(−/−) mice, which may suggest
the involvement of P-gp. Interestingly, up-regulation of
canalicular P-gp has been observed in rats after trabectedin
administration [42], even if the expression of other pumps
and enzymes may have been altered. It is unlikely that up-
regulation of P-gp results in a markedly enhanced hepato-
biliary excretion of trabectedin, but it may aid in the
elimination of other, possibly toxic, metabolites of trabectedin.
Increased efflux of toxic metabolites could explain reduced
toxicity in the wild-type mice and slightly increased toxicity in
mdr1a/1b(−/−) mice after repeated dosing.
The degree of hepatotoxicity was also determined by
gender. However, the hepatotoxicity is not a dose-limiting
event per se. While both strains were dosed at 250 μg/kg
(the MTD in both strains), female wild-type mice experienced
(almost) no hepatotoxicity, whereas we observed serious
hepatoxicity in female mdr1a/1b(−/−) mice. Apparently,
there are other trabectedin toxicities resulting in a decreased
well-being, and ultimately death. Pathology of the animals
revealed other toxicities, however, none of these were clearly
dose limiting either. The bone marrow depletion observed
4 days after administration, which had recovered at day 14,
is in keeping with the dose limiting toxicities observed in
humans (thrombocytopenia, neutropenia, pancytopenia) [12].
Pathological examination of mdr1a/1b(−/−) and wild-type
mice revealed some striking differences in toxicity at the
organ-level. The observations in the liver are relatively mild
and in line with the reversible nature of the hepatotoxicity.
The degeneration of the kidney tubules and the degenerative
cardiomyopathy in female mdr1a/1b(−/−) mice is suggestive
of a protective role for P-gp. However, the involvement of
other enzymes, whose expression may be affected by the
absence of P-gp, cannot be ruled out. The absence of similar
pathologic effects in male mdr1a/1b(−/−) mice may be due
to the lower dose administered (MTD 150 μg/kg relative to
250 μg/kg in females).
In conclusion, P-gp is important for the in vivo
disposition of trabectedin as its expression decreased the
distribution into the testis and the brain. However, P-gp
does not significantly influence the clearance of trabectedin.
Consequently, differences in toxicities between wild-type
and mdr1a/1b(−/−) mice could not adequately be explained
by differences in plasma exposure of unchanged drug. This
suggests that either tissue-specific distribution of trabectedin,
or metabolites of trabectedin determine its toxicity profile.
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